Columbia

The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.

Exome sequencing and case-control analyses on hundreds of stillborn cases led to more than a dozen apparent risk genes and additional loss-of-function intolerant genes.

The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.

The test is designed to detect the SARS-CoV-2 nucleocapsid gene in nasopharyngeal, oropharyngeal, nasal, and midturbinate nasal swab samples.

Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.

Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.